SCHEMBL3812903

SCHEMBL3812903

COc1cc(C(C)O)cc(OC)c1C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
BLM P54132 2/20 0.37
NFKB1 P19838 1/20 0.37
SLC22A3 O75751 1/20 0.37
UGT2B7 P16662 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15783782 0.84 HDAC4 (0.44) MAPTTSHRCYP3A4PPARGPPARD
SCHEMBL15241086 0.80 PKM (0.47) MAPTTSHRCYP3A4PPARDNPSR1
SCHEMBL8115552 0.80 MAPT (0.56) MAPTCYP3A4L3MBTL1TUBB4ATUBB
SCHEMBL1613430 0.78 MGAM (0.41) MAPTTSHRCYP3A4PPARGPPARD
SCHEMBL15417892 0.78 CNR2 (0.40) MAPTTSHRCYP3A4PPARGPPARD
SCHEMBL11983745 0.77 CYP3A4 (0.56) MAPTCYP3A4PDE3BPDE3A
SCHEMBL31545189 0.75 GABRA1 (0.44) TSHRCYP3A4NPSR1GAABLM
SCHEMBL27595576 0.75 CNR2 (0.42) MAPTTSHRNPSR1L3MBTL1KMT2A
SCHEMBL11983792 0.75 ALDH1A1 (0.48) CYP3A4CYP1A2GAAPDE3BPDE3A
SCHEMBL11436443 0.75 ACHE (0.54) CYP3A4GAAHDAC4HDAC8PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101434517-B 1, 2-diphenylethylene derivatives for the treatment of immune disorders BEIJING WENFENG TIANJI PHARMACEUTICAL TECHNOLOGY CO LTD 2014-08-27 CN disclosed
US-8487009-B2 1,2-diphenylethene derivatives for treatment of immune diseases GLAXO GROUP LIMITED (GB) 2013-07-16 US disclosed
EP-1368306-B1 NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES WELICHEM BIOTECH INC (CA) 2013-01-16 EP disclosed
US-20090149548-A1 NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES WELICHEM BIOTECH, INC. (CA) 2009-06-11 US disclosed
CN-101434517-A 1, 2-diphenylethylene derivatives for the treatment of immune disorders WELICHEM BIOTECH INC (CN) 2009-05-20 CN disclosed
CN-100462354-C 1, 2-diphenylethylene derivatives for the treatment of immune disorders WELICHEM BIOTECH INC (CN) 2009-02-18 CN disclosed
US-20040102517-A1 Modulators of T- cells, neutrophils, macrophages and their associated cytokines GLAXO GROUP LIMITED (GB) 2004-05-27 US disclosed
CN-1455766-A 1, 2-diphenylethylene derivatives for the treatment of immune disorders WELICHEM BIOTECH INC (CA) 2003-11-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149548-A1 NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES IL2, IFNG, NFATC1 MAPT 1934/4885TSHR 2714/4885CYP3A4 2152/4885
US-20040102517-A1 Modulators of T- cells, neutrophils, macrophages and their associated cytokines IL2, NFATC1, IFNG MAPT 1655/4885TSHR 1631/4885CYP3A4 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.